A PYMNTS Company

Australia: ACCC loses appeal against Pfizer over Lipitor sales

By  |  May 27, 2018

An Australian court dismissed an appeal by the nation’s anti-trust watchdog in a case against Pfizer in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor, reported Reuters.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The Australian Competition and Consumer Commission (ACCC) announced on Friday, May 25, it was considering the judgment and remained committed to pursuing cases involving “misuse of market power”.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    “The ACCC brought this appeal because it was concerned that Pfizer’s use of its market position as supplier of the top selling branded atorvastatin immediately before generic products were able to enter the market harmed the competitive process and therefore consumers,”  Chairman Rod Sims said in a statement.

     

    Full Content: Business Insider

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.